PinnyPeptide

Adamax vs DNSP-11

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Adamax

Cognitive

Adamantyl-capped Semax derivative — a more lipophilic, longer-acting nootropic analog.

Peptide B

DNSP-11

Cognitive

Eleven-amino-acid peptide derived from the GDNF prodomain — neuroprotective for dopamine neurons.

Typical vial

5 mg

Typical dose

100-500 mcg

Half-life

Estimated longer than Semax (~hours, uncharacterized)

FDA status

Not FDA approved.

Typical vial

5 mg

Typical dose

Variable (research-specific) mcg

Half-life

Short; precise value uncharacterized

FDA status

Not FDA approved.

Adamax effects

  • Hypothesized BDNF upregulation in hippocampus / cortex
  • Theoretical longer duration of action vs. Semax
  • Theoretical improved blood-brain barrier penetration
  • Cognitive enhancement claims (attention, memory)
  • Mood and stress-resilience effects (extrapolated from Semax)

DNSP-11 effects

  • Dopaminergic neuroprotection in Parkinson's models
  • Increased dopamine production in dopaminergic neurons
  • Improved motor function in 6-OHDA and MPTP models
  • Mechanism distinct from full-length GDNF
  • Investigational for Parkinson's and related disorders

Adamax side effects

  • Largely uncharacterized in published literature
  • By analogy with Semax: mild headache, sleep disturbance, irritability at high doses
  • Theoretical: adamantyl-related effects on dopamine signaling
  • Injection-site or intranasal irritation

DNSP-11 side effects

  • Essentially uncharacterized in humans
  • Possible local tissue effects with intracerebroventricular delivery
  • Theoretical: off-target effects on non-dopaminergic neurons
  • Injection-site reactions

Adamax dosing ranges

Cognitive research (intranasal)

100-300 mcg · Once or twice daily · 14-30 days per cycle

Subcutaneous research

100-500 mcg · Once daily · 14-30 days per cycle

DNSP-11 dosing ranges

Research / Parkinson's models (preclinical)

Variable per protocol · ICV or peripheral routes · Per research design

Full Adamax guide → Full DNSP-11 guide →

Adamax vs DNSP-11 — common questions

What is the difference between Adamax and DNSP-11?

Adamax: Adamantyl-capped Semax derivative — a more lipophilic, longer-acting nootropic analog. Typical dose 100-500 mcg. DNSP-11: Eleven-amino-acid peptide derived from the GDNF prodomain — neuroprotective for dopamine neurons. Typical dose Variable (research-specific) mcg. Both fall under the Cognitive category.

Can you stack Adamax and DNSP-11?

Stacking Adamax with DNSP-11 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Adamax or DNSP-11?

Adamax is typically dosed: Once or twice daily for Cognitive research (intranasal); Once daily for Subcutaneous research. DNSP-11 is typically dosed: ICV or peripheral routes for Research / Parkinson's models (preclinical).

Are Adamax and DNSP-11 FDA approved?

Adamax: Not FDA approved. DNSP-11: Not FDA approved.

Related peptide comparisons

acth-1-39 vs adamaxadamax vs colivelinadamax vs dihexaadamax vs p21adamax vs pe22-28colivelin vs dnsp-11

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free